Truvestments Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Truvestments Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.4K	Sell	160 -4	-2%	-$1.86K	0.01%	447
2025 Q4	$74.4K	Sell	164 -5	-3%	-$2.15K	0.01%	389
2025 Q3	$66.2K	Buy	169 +33	+24%	+$13.8K	0.01%	402
2025 Q2	$60.5K	Buy	136 +40	+42%	+$18.4K	0.01%	368
2025 Q1	$46.5K	Sell	96 -3	-3%	-$1.4K	0.01%	411
2024 Q4	$39.9K	Buy	99 +23	+30%	+$10.7K	0.01%	404
2024 Q3	$35.3K	Buy	+76	New	+$36.5K	0.01%	411
2023 Q1	–	Sell	-2	Closed	-$578	–	938
2022 Q4	$578	Buy	+2	New	+$610	﹤0.01%	859
2021 Q1	–	Sell	-55	Closed	-$12K	–	685
2020 Q4	$12K	Buy	+55	New	+$12.6K	0.01%	419
2020 Q3	–	Sell	-5	Closed	-$1K	–	548
2020 Q2	$1K	Buy	+5	New	+$1.36K	﹤0.01%	554
2019 Q4	–	Sell	-31	Closed	-$5K	–	583
2019 Q3	$5K	Hold	31	–	–	﹤0.01%	583
2019 Q2	$6K	Hold	31	–	–	﹤0.01%	604
2019 Q1	$6K	Buy	+31	New	+$5.73K	﹤0.01%	586
2018 Q3	$6K	Buy	+31	New	+$5.52K	﹤0.01%	722

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Truvestments Capital's VRTX Position: Q1 2026 in Review

Truvestments Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, selling an estimated $1.86K and leaving 160 shares worth $71.4K. The position accounts for 0.01% of the portfolio, ranked #447.

Truvestments Capital first reported a position in VRTX in Q3 2018 and has held it in 14 quarters since. The position peaked at $74.4K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Truvestments Capital held 160 shares of Vertex Pharmaceuticals worth $71.4K as of Q1 2026.
Truvestments Capital sold 4 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.86K.
Vertex Pharmaceuticals made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #447 holding.
Truvestments Capital first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 14 quarters since.
Truvestments Capital's Vertex Pharmaceuticals position peaked at $74.4K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.